Sector Gamma As Increases Stake in Portola Pharmaceuticals (PTLA); Bank Of Hawaii Holding in Texas Instruments (TXN) Raised by $454,429

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Logo

Bank Of Hawaii increased its stake in Texas Instruments Inc (TXN) by 13.99% based on its latest 2018Q3 regulatory filing with the SEC. Bank Of Hawaii bought 4,247 shares as the company’s stock declined 13.40% with the market. The institutional investor held 34,610 shares of the semiconductors company at the end of 2018Q3, valued at $3.71M, up from 30,363 at the end of the previous reported quarter. Bank Of Hawaii who had been investing in Texas Instruments Inc for a number of months, seems to be bullish on the $101.27 billion market cap company. The stock increased 0.67% or $0.71 during the last trading session, reaching $107.15. About 5.97M shares traded. Texas Instruments Incorporated (NASDAQ:TXN) has declined 4.07% since February 14, 2018 and is downtrending. It has underperformed by 4.07% the S&P500. Some Historical TXN News: 19/04/2018 – Axcelis Wins 2017 Texas Instruments Supplier Excellence Award; 13/04/2018 – Texas Instruments Senior VP of Technology & Manufacturing Kevin J. Ritchie to Retire Nov. 1; 18/04/2018 – Nuveen Santa Barbara Adds Texas Instruments; 19/04/2018 – Boston Semi Equipment Recognized for Excellence by Texas Instruments; 26/03/2018 – Texas Instruments to webcast its annual meeting of stockholders; 21/05/2018 – TI Chief Financial Officer Rafael Lizardi to speak at Bank of America Merrill Lynch investor conference; 22/05/2018 – Texas Instruments launches “STEM Squad” to keep students’ math and science skills sharp over the summer; 17/05/2018 – TI COO Brian Crutcher to speak at Bernstein investor conference; 25/04/2018 – TEXAS INSTRUMENTS INC TXN.O : DEUTSCHE BANK RAISES TARGET PRICE TO $107 FROM $105; 24/04/2018 – Texas Instruments Expects Annual Operating Tax Rate About 16% Starting in 2019, 20% in 2018

Sector Gamma As increased its stake in Portola Pharmaceuticals Inc (PTLA) by 34.31% based on its latest 2018Q3 regulatory filing with the SEC. Sector Gamma As bought 68,901 shares as the company’s stock declined 24.91% with the market. The institutional investor held 269,701 shares of the health care company at the end of 2018Q3, valued at $7.18M, up from 200,800 at the end of the previous reported quarter. Sector Gamma As who had been investing in Portola Pharmaceuticals Inc for a number of months, seems to be bullish on the $1.97 billion market cap company. The stock increased 0.92% or $0.27 during the last trading session, reaching $29.64. About 1.02 million shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has declined 60.37% since February 14, 2018 and is downtrending. It has underperformed by 60.37% the S&P500. Some Historical PTLA News: 24/04/2018 – DoJ CA Northern: Portola Valley Resident Sentenced In Bank Fraud Scheme; 25/04/2018 – Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; 03/05/2018 – U.S. FDA Approves Portola Pharmaceuticals’ Andexxa®, First and Only Antidote for the Reversal of Factor Xa Inhibitors; 03/05/2018 – U.S. FDA APPROVES PORTOLA PHARMACEUTICALS’ ANDEXXA®, FIRST AND ONLY ANTIDOTE FOR THE REVERSAL OF FACTOR XA INHIBITORS; 10/05/2018 – Two New California Pacific Homes Neighborhoods Debut This Summer in Portola Springs® Village; 25/04/2018 – Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology; 05/03/2018 Portola Pharmaceuticals to Host Webcast Event and Conference Call at ACC.18 to Discuss Late-Breaking Oral Presentation Highligh; 12/03/2018 – Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent AndexXa; 24/05/2018 – Portola Pharmaceuticals Receives $100M Milestone Payment From HealthCare Royalty Partners for FDA Approval of Andexxa; 23/03/2018 – EMA CHMP shows more teeth than FDA again this month $PTLA betrixaban — data were not considered reliable

Investors sentiment decreased to 1.21 in Q3 2018. Its down 0.32, from 1.53 in 2018Q2. It fall, as 22 investors sold PTLA shares while 48 reduced holdings. 29 funds opened positions while 56 raised stakes. 65.93 million shares or 8.84% more from 60.58 million shares in 2018Q2 were reported. Millennium Mngmt Limited Liability Com reported 0.01% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Moreover, State Street Corporation has 0.01% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Swiss Bancorporation invested in 107,957 shares or 0% of the stock. Wilbanks Smith Thomas Asset Mgmt Limited Liability Co, a Virginia-based fund reported 250 shares. Blair William And Company Il owns 88,191 shares for 0.01% of their portfolio. Magnetar Fin Llc stated it has 15,000 shares. Hudson Bay Management Ltd Partnership owns 132,500 shares. Smith Asset Group Limited Partnership, a Texas-based fund reported 8,100 shares. First Hawaiian Retail Bank invested 0% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Fiera holds 27,784 shares. Royal Bankshares Of Canada holds 0% or 9,748 shares. Family Mgmt accumulated 17,000 shares. Virtu Financial Limited Co has 9,239 shares. Schwab Charles Inv Management reported 0.01% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Ny State Common Retirement Fund holds 72,500 shares or 0% of its portfolio.

Since August 21, 2018, it had 1 buy, and 1 insider sale for $8.88 million activity. 390,000 shares valued at $10.08 million were bought by BIRD JEFFREY W on Tuesday, August 21.

More notable recent Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) news were published by: Nasdaq.com which released: “Peek Under The Hood: IYY Has 14% Upside – Nasdaq” on January 22, 2019, also Nasdaq.com with their article: “Portola’s (PTLA) Lymphoma Candidate Gets Orphan Drug Status – Nasdaq” published on September 26, 2018, Seekingalpha.com published: “CHMP extends review period for Portola’s Ondexxya until late February – Seeking Alpha” on December 11, 2018. More interesting news about Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) were released by: Nasdaq.com and their article: “Why Portola Pharmaceuticals (PTLA) Could Be Positioned for a Slump – Nasdaq” published on March 12, 2018 as well as Nasdaq.com‘s news article titled: “Portola (PTLA) Down as CHMP Defers Review Date for Ondexxya – Nasdaq” with publication date: December 12, 2018.

Sector Gamma As, which manages about $637.80 million US Long portfolio, decreased its stake in Anthem Inc (NYSE:ANTM) by 4,397 shares to 83,513 shares, valued at $22.89M in 2018Q3, according to the filing. It also reduced its holding in Ionis Pharmaceuticals Inc by 100,806 shares in the quarter, leaving it with 202,434 shares, and cut its stake in Lilly Eli & Co (NYSE:LLY).

Among 7 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Portola Pharmaceuticals had 48 analyst reports since August 5, 2015 according to SRatingsIntel. Oppenheimer maintained it with “Buy” rating and $8000 target in Sunday, July 23 report. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) earned “Buy” rating by Citigroup on Monday, June 26. On Wednesday, December 13 the stock rating was maintained by Oppenheimer with “Buy”. Credit Suisse maintained the stock with “Outperform” rating in Tuesday, December 27 report. The stock has “Buy” rating by Oppenheimer on Monday, June 26. Oppenheimer maintained the shares of PTLA in report on Monday, January 15 with “Buy” rating. Credit Suisse maintained the shares of PTLA in report on Thursday, August 10 with “Hold” rating. The rating was maintained by Credit Suisse on Monday, March 28 with “Outperform”. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has “Buy” rating given on Friday, December 1 by Goldman Sachs. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) earned “Neutral” rating by Credit Suisse on Monday, August 27.

Bank Of Hawaii, which manages about $1.30B and $1.30B US Long portfolio, decreased its stake in Ishares Core Msci (IEMG) by 22,765 shares to 259,570 shares, valued at $13.44M in 2018Q3, according to the filing. It also reduced its holding in Vanguard (BND) by 22,558 shares in the quarter, leaving it with 176,281 shares, and cut its stake in Facebook Inc (NASDAQ:FB).

Since October 25, 2018, it had 1 buying transaction, and 19 sales for $32.23 million activity. Shares for $2.34 million were sold by ANDERSKOUV NIELS. Shares for $683,813 were sold by BLINN MARK A. Shares for $936,455 were sold by Flessner Kyle M on Thursday, January 31. 21,337 shares were sold by XIE BING, worth $2.21 million on Friday, January 25. $601,658 worth of stock was sold by Whitaker Darla H on Thursday, January 31. CARP DANIEL A sold $1.53M worth of stock or 14,749 shares.

Investors sentiment increased to 1.19 in 2018 Q3. Its up 0.05, from 1.14 in 2018Q2. It improved, as 44 investors sold TXN shares while 372 reduced holdings. 125 funds opened positions while 372 raised stakes. 782.89 million shares or 1.44% less from 794.31 million shares in 2018Q2 were reported. Moreover, Leavell Invest has 0.44% invested in Texas Instruments Incorporated (NASDAQ:TXN). Ballentine Prns holds 0.09% or 15,229 shares. Covenant Multifamily Offices Lc holds 0.8% or 21,206 shares. Dekabank Deutsche Girozentrale stated it has 1.49M shares or 0.99% of all its holdings. 1,082 were accumulated by Hanseatic Services. Alecta Pensionsforsakring Omsesidigt reported 2.22M shares. North Star Inv stated it has 0.17% of its portfolio in Texas Instruments Incorporated (NASDAQ:TXN). Naples Glob Advsrs holds 0.46% or 14,854 shares. Massachusetts Financial Ma has 1.05% invested in Texas Instruments Incorporated (NASDAQ:TXN) for 23.76 million shares. Montag A Assoc reported 19,217 shares or 0.18% of all its holdings. Gabelli & Com Investment Advisers has 0.03% invested in Texas Instruments Incorporated (NASDAQ:TXN). Horseman Mgmt Ltd has 20,000 shares. Plante Moran Fincl Ltd Liability Co invested 0.15% of its portfolio in Texas Instruments Incorporated (NASDAQ:TXN). Sfe Investment Counsel reported 0.54% stake. Headinvest Ltd Llc, Maine-based fund reported 51,839 shares.

Among 43 analysts covering Texas Instruments (NASDAQ:TXN), 21 have Buy rating, 2 Sell and 20 Hold. Therefore 49% are positive. Texas Instruments had 135 analyst reports since July 24, 2015 according to SRatingsIntel. The stock has “Overweight” rating by Morgan Stanley on Wednesday, July 26. The company was maintained on Thursday, April 28 by Cowen & Co. The stock has “Buy” rating by Jefferies on Wednesday, May 31. As per Wednesday, January 25, the company rating was maintained by Drexel Hamilton. On Wednesday, July 11 the stock rating was upgraded by Longbow to “Buy”. FBR Capital maintained it with “Neutral” rating and $123 target in Wednesday, July 25 report. The stock of Texas Instruments Incorporated (NASDAQ:TXN) earned “Market Perform” rating by Cowen & Co on Thursday, October 27. On Thursday, October 18 the stock rating was upgraded by Goldman Sachs to “Neutral”. The stock of Texas Instruments Incorporated (NASDAQ:TXN) earned “Neutral” rating by B. Riley & Co on Thursday, October 22. On Thursday, January 28 the stock rating was maintained by M Partners with “Neutral”.

Texas Instruments Incorporated (NASDAQ:TXN) Institutional Positions Chart